genetics

A New Genetic Test To Help You Understand Your Risk For A Prostate Cancer Recurrence

Base on a recently published news release, a prospective study performed and funded by the commercial company GenomeDx Biosciences showed that their new Decipher Cancer Classifier test reclassifies the tumor aggressiveness in men who have had surgery as their primary prostate cancer treatment. According to the company, this newly validated test will improve clinical decision-making following a radical prostatectomy. In this validation study, their Decipher Post-Op test was able to reclassified the tumor aggressiveness in a large number of men based on the genomic risk assessment as compared to our current clinical and pathological risk assessment tools. The company claims [...]

By | September 12th, 2016|Genetic testing, genetics, prognostic tools, Uncategorized|0 Comments

Understanding the Risk Factors for Hereditary Prostate Cancer – A Surprise

We often refer to prostate cancer as a family affair, or rather being passed on from father to son, etc. This is only partially true because there is still more prostate cancer diagnosed in men without any family history. For those cancers that are passed on from one family member to another it is important to understand the risks. This includes the risks for both being diagnosed and the risks for aggressiveness. It is generally accepted that if your brother has prostate cancer your risk of also having prostate cancer is doubled. But what does this really mean? Yes, you [...]

Myriad Genetics Attempts To Deny Patients Their Personal Genetic Information

 In 2013, Myriad Genetic failed – in a case that was heard in the United States Supreme Court - to patent the BRCA1 and BRCA2 genes.  We all have these two genes which, when they mutate, are associated with breast, ovarian and prostate cancers. If Myriad succeeded, they would have controlled patents on these genes and could establish a monopoly on all research and testing of these genes. Myriad is now facing a lawsuit over  denying their clients access to their own genetic information.  The four plaintiffs in the action underwent genetic testing with Myriad to determine their hereditary risk [...]

Genetic Biomarker Predicts Peripheral Neuropathy Associated With Docetaxel Chemotherapy For Prostate Cancer

According to researchers at the H. Lee Moffitt Cancer Center & Research Institute, men with a mutation in their VAC14 gene are more susceptible to Docetaxil chemotherapy induced neuropathy and nerve pain. This debilitating side effect results from damage to the peripheral nerves and is felt by the man as weakness, numbness and pain most likely felt in the hands and feet. The Moffitt study was published online in the journal Clinical Cancer Research. The researchers analyzed the DNA of 623 men who had participated in a randomized phase 3 clinical trial that included docetaxel chemotherapy therapy. A total of [...]

スーパーコピーブランド ロレックススーパーコピー オメガスーパーコピー ブルガリスーパーコピー ブライトリングスーパーコピー カルティエスーパーコピー シャネル時計コピー IWCスーパーコピー フランクミュラースーパーコピー パネライスーパーコピー タグホイヤースーパーコピー ウブロスーパーコピー ガガミラノスーパーコピー ルイヴィトンスーパーコピー シャネルスーパーコピー エルメススーパーコピー グッチスーパーコピー ボッテガヴェネタスーパーコピー プラダスーパーコピー セリーヌスーパーコピー ロレックススーパーコピー ウブロスーパーコピー